We are live on
!
Find out more
FV2GP
Flagship Ventures 2007 General Partner Portfolio holdings
AUM
$107M
This Fund
S&P 500
This Quarter
Est. Return
-2.95%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$157M
AUM Growth
–
Cap. Flow
+$146M
Cap. Flow
% of AUM
93.34%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
4
New
4
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Agios Pharmaceuticals
AGIO
|
+$88M |
| 2 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
+$43.2M |
| 3 |
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
|
+$13.9M |
| 4 |
BGMD
BG MEDICINE INC COM STK NEW
BGMD
|
+$1.28M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 58.97% |
Similar funds
EIGI
BPV
HDE
WCM
NCM
WCM
EGA
TAG
Flagship Ventures 2007 General Partner's Q4 2013 Portfolio in Review
Q4 2013 is the first quarter with a 13F filing on record for Flagship Ventures 2007 General Partner, which disclosed 4 positions worth $157M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Agios Pharmaceuticals: 3,860,738 shares worth $92.5M.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets.
- Flagship Ventures 2007 General Partner's largest Q4 2013 buy was Agios Pharmaceuticals: 3,860,738 shares worth $92.5M.
- Flagship Ventures 2007 General Partner's ten largest holdings make up 100% of its $157M portfolio in Q4 2013.
- Flagship Ventures 2007 General Partner disclosed 4 positions in Q4 2013, its first 13F filing on record.
Based on Flagship Ventures 2007 General Partner's 13F filing for Q4 2013, filed 10 Feb 2014.